<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Sun, 19 Apr 2026 17:39:45 -0400--><rss version="2.0">
    <channel>
        <title>Atara Biotherapeutics (ATRA) Press Releases</title>
        <link>https://investors.atarabio.com/news-events/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/atarabio/files/theme/images/logo-sm.png</url>
                <title>Atara Biotherapeutics Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress]]></title>
                <description><![CDATA[]]></description>
                <link>https://investors.atarabio.com/news-events/press-releases/detail/384/atara-biotherapeutics-announces-fourth-quarter-and-full</link>
                <pubDate>Mon, 16 Mar 26 16:05:00 -0400</pubDate>
                <guid>https://investors.atarabio.com/news-events/press-releases/detail/384/atara-biotherapeutics-announces-fourth-quarter-and-full</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel]]></title>
                <description><![CDATA[]]></description>
                <link>https://investors.atarabio.com/news-events/press-releases/detail/383/atara-biotherapeutics-provides-regulatory-update-on</link>
                <pubDate>Thu, 12 Mar 26 08:05:00 -0400</pubDate>
                <guid>https://investors.atarabio.com/news-events/press-releases/detail/383/atara-biotherapeutics-provides-regulatory-update-on</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel]]></title>
                <description><![CDATA[]]></description>
                <link>https://investors.atarabio.com/news-events/press-releases/detail/382/atara-biotherapeutics-provides-regulatory-update-on</link>
                <pubDate>Tue, 03 Mar 26 08:05:00 -0500</pubDate>
                <guid>https://investors.atarabio.com/news-events/press-releases/detail/382/atara-biotherapeutics-provides-regulatory-update-on</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Atara Biotherapeutics Provides a Business Update]]></title>
                <description><![CDATA[]]></description>
                <link>https://investors.atarabio.com/news-events/press-releases/detail/381/atara-biotherapeutics-provides-a-business-update</link>
                <pubDate>Mon, 23 Feb 26 08:00:00 -0500</pubDate>
                <guid>https://investors.atarabio.com/news-events/press-releases/detail/381/atara-biotherapeutics-provides-a-business-update</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)]]></title>
                <description><![CDATA[]]></description>
                <link>https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business</link>
                <pubDate>Mon, 12 Jan 26 08:00:00 -0500</pubDate>
                <guid>https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress]]></title>
                <description><![CDATA[]]></description>
                <link>https://investors.atarabio.com/news-events/press-releases/detail/379/atara-biotherapeutics-announces-third-quarter-financial</link>
                <pubDate>Wed, 12 Nov 25 09:00:00 -0500</pubDate>
                <guid>https://investors.atarabio.com/news-events/press-releases/detail/379/atara-biotherapeutics-announces-third-quarter-financial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Atara Biotherapeutics Announces Changes to Its Board of Directors]]></title>
                <description><![CDATA[]]></description>
                <link>https://investors.atarabio.com/news-events/press-releases/detail/378/atara-biotherapeutics-announces-changes-to-its-board-of</link>
                <pubDate>Wed, 03 Sep 25 18:00:00 -0400</pubDate>
                <guid>https://investors.atarabio.com/news-events/press-releases/detail/378/atara-biotherapeutics-announces-changes-to-its-board-of</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress]]></title>
                <description><![CDATA[]]></description>
                <link>https://investors.atarabio.com/news-events/press-releases/detail/377/atara-biotherapeutics-announces-second-quarter-financial</link>
                <pubDate>Mon, 11 Aug 25 16:01:00 -0400</pubDate>
                <guid>https://investors.atarabio.com/news-events/press-releases/detail/377/atara-biotherapeutics-announces-second-quarter-financial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease]]></title>
                <description><![CDATA[]]></description>
                <link>https://investors.atarabio.com/news-events/press-releases/detail/376/atara-biotherapeutics-announces-u-s-fda-acceptance-and</link>
                <pubDate>Thu, 24 Jul 25 08:00:00 -0400</pubDate>
                <guid>https://investors.atarabio.com/news-events/press-releases/detail/376/atara-biotherapeutics-announces-u-s-fda-acceptance-and</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)]]></title>
                <description><![CDATA[]]></description>
                <link>https://investors.atarabio.com/news-events/press-releases/detail/375/atara-biotherapeutics-provides-regulatory-and-business</link>
                <pubDate>Mon, 14 Jul 25 08:00:00 -0400</pubDate>
                <guid>https://investors.atarabio.com/news-events/press-releases/detail/375/atara-biotherapeutics-provides-regulatory-and-business</guid>
                                                                            </item>
            </channel>
</rss>